ScienHub and Its Key Role in the SUPERNOVA Study on Preventive Monoclonal Antibodies Against COVID-19

The SUPERNOVA study evaluates the efficacy of preventive monoclonal antibodies against SARS-CoV-2 in patients with antibody synthesis deficiencies, whether due to primary causes or secondary to biological or immunosuppressive treatments.

ScienHub’s contribution to this study has been essential, as it was responsible for coordinating and executing all procedures, as well as conducting thorough follow-ups over the course of a year through weekly phone calls to assess the onset of COVID-19 symptoms in enrolled patients. With 30 participating patients, our center was the second most active hospital in Spain in terms of participation.

Approval of Sipavibart

Recently, AstraZeneca announced the approval of sipavibart (AZD3152) in Europe and Japan for the prevention of symptomatic COVID-19 in immunocompromised populations, based on the results of the SUPERNOVA study.

These findings reinforce ScienHub’s crucial role in advancing preventive strategies for vulnerable populations and highlight the importance of clinical research in the fight against COVID-19.

0
    0
    Your Cart
    Your cart is emptyReturn to Shop